Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the ...

Metsera's lead asset is MET-097i, billed as an ultra-long-acting GLP-1 receptor agonist with a profile that could challenge ...

There’s still scope for a new generation of drugs to replace weight-loss market leaders like Novo Nordisk A/S’s Wegovy, ...

A new review highlights the future of anti-obesity medications that could outperform today's already blockbuster drugs like ...

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

Next-gen obesity biotech Metsera has filed to debut on the public markets, proposing an IPO nine months after emerging. | ...

Compounding pharmacies make their own versions of weight loss drugs at a fraction of the price but there are some drawbacks.

Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

The changes reflect “a cultural shift” around obesity medications, said Diana Zuckerman, president of the nonprofit National ...

A new request by Ozempic manufacturer Novo Nordisk could limit the availability of a type of GLP-1—semaglutides—to local ...